Results 31 to 40 of about 88,050 (335)

Aspirin resistance in patients with ischemic stroke

Southern Clinics of Istanbul Eurasia, 2019
INTRODUCTION[|]Aspirin is the basic agent of antithrombotic treatment in ischemic cerebrovascular disease (CVD) patients. However several patients don't respond to treatment and therefore aspirin resistance term has been used lately.
Anıl Bulut, Sultan Çağırıcı, Vildan Yayla, Murat Çabalar, Songül Şenadım   +4 more
doaj   +1 more source

The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis. [PDF]

PLoS ONE, 2013
OBJECTIVE: Evidence is mounting suggesting that a strong genetic component underlies aspirin insensitivity. To generate more information, we aimed to evaluate the association of four common polymorphisms (rs3842787, rs20417, rs201184269, rs1126643) from ...
Zhiyuan Weng, Xiaobo Li, Yuqiong Li, Jinxiu Lin, Feng Peng, Wenquan Niu   +5 more
doaj   +1 more source

Aspirin resistance: position paper of the Working Group on Aspirin Resistance [PDF]

Journal of Thrombosis and Haemostasis, 2005
Aspirin irreversibly acetylates serine 529 of cyclooxygenase (COX)-1, resulting in inhibition of thromboxane A2 generation by platelets and prostacyclin by endothelial cells [1]. Because platelets lack the synthetic machinery to generate significant amounts of new COX, aspirin-induced COX-1 inhibition lasts for the lifetime of the platelet. In contrast,
MICHELSON AD, CATTANEO M, EIKELBOOM JW, GURBEL P, KOTTKE MARCHANT K, KUNICKI TJ, PULCINELLI, FABIO MARIA, CERLETTI C, RAO AK, PLATELET PHYSIOLOGY SUBCOMMITTEE OF THE SCIENTIFIC AND STANDARDIZATION COMMITTEE OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS, WORKING GROUP ON ASPIRIN RESISTANCE   +10 more
openaire   +6 more sources

Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study. [PDF]

, 2014
ObjectiveThere is insufficient evidence on which to base a recommendation for optimal antiplatelet therapy following a stroke while on aspirin. The objective was to compare clopidogrel initiation vs aspirin reinitiation for vascular risk reduction among ...
Chang, Ku-Chou, Lee, Hsuei-Chen, Lee, Jiann-Der, Lee, Meng, Lee, Tsong-Hai, Ovbiagele, Bruce, Rao, Neal M, Saver, Jeffrey L, Wang, Hui-Hsuan, Wu, Chih-Ying, Wu, Yi-Ling   +10 more
core   +1 more source

PENGARUH DIABETES MELLITUS TERHADAP RESISTENSI ASPIRIN PADA PASIEN STROKE ISKEMIK DI RUMAH SAKIT BETHESDA YOGYAKARTA

Pharmaciana, 2014
The secondary prevention of ischemic stroke can be implemented by giving aspirin. However, some cases of aspirin resistance have been found. The purpose of this study was to examine the influence of diabetes mellitus on the risk of aspirin resistance ...
Hardi Astuti Witasari, Rizaldy Taslim Pinzon, Erna Kristin   +2 more
doaj   +1 more source

Aspirin and clopidogrel resistance; a neglected gap in stroke and cardiovascular practice in Iran: a systematic review and meta-analysis

Thrombosis Journal, 2023
Objective Antiplatelet drugs, such as Aspirin and Clopidogrel (Plavix) are effective in the primary prevention of thromboembolic events. They are commonly used to reduce the risk of recurrence of thromboembolism.
Mohammad Parsa-kondelaji, Hassan Mansouritorghabeh   +1 more
doaj   +1 more source

Aspirin resistance and atherothrombosis [PDF]

, 2007
PUC-SP Faculdade de Medicina de SorocabaUNIFESP-EPMPUC-SP Faculdade de Medicina de Sorocaba Departamento de Clínica MédicaUNIFESP ...
Beteli, Camila Baumann, Gabriel, Edmo Atique, Gabriel, Sthefano Atique, Job, José Roberto Pretel Pereira, Tanighuchi, Rodrigo Seiji, Tristão, Cristiane Knopp   +5 more
core   +4 more sources

Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]

, 2018
© The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast, AD Michelson, B Labarthe, B Shen, C Patrono, CT Ammollo, D Capodanno, D Gailani, DA Gorog, Diana A. Gorog, DM Coenen, E Álvarez, ER Bates, F Kabirian, F Müller, F Semeraro, G Stephens, H Brogren, HE Speich, HE Speich, HJ Weiss, HJ Weiss, HR Baumgartner, J Zilberman-Rudenko, JD McFadyen, JI Weitz, JM Cosemans, JP Collet, JP Collet, K Hosokawa, K Nagatsuka, KS Sakariassen, L Valerio, LF Brass, M Cattaneo, M Farag, M Humbert, M Larsson, M Li, M Ungerer, MA Bailey, MI Furman, MJ Price, ML Montfoort von, MS Sabatine, P Andre, P Seizer, PA Borne von dem, PP Wadowski, R Hellmuth, R Nergiz-Unal, RA Ajjan, S Goto, S Goto, SA Shaya, SB Larsen, SJ Marciniak, T Heitzer, T Renné, VT Turitto, VT Turitto, WA Schumacher, WS Nesbitt, X Wang, Y Yano, YC Lau, ZM Ruggeri   +66 more
core   +2 more sources

The genetics of aspirin resistance

International Journal of Clinical Practice, 2007
Aspirin is widely used for the prophylaxis of cardiovascular events in patients with cardiovascular risk factors or established atherosclerotic disease. However, despite aspirin treatment, a substantial number of patients experience recurrent events. Such 'aspirin resistance' is generally defined as failure of aspirin to produce an expected biological ...
Goodman, T, Sharma, P, Ferro, A
openaire   +3 more sources

The prognostic utility of tests of platelet function for the detection of 'aspirin resistance' in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation. [PDF]

, 2015
BACKGROUND: The use of aspirin is well established for secondary prevention of cardiovascular disease. However, a proportion of patients suffer repeat cardiovascular events despite being prescribed aspirin treatment.
Bayliss, S, Dretzke, J, Ensor, J, Fitzmaurice, D, Hodgkinson, J, Jowett, S, Lordkipanidzé, M, Moloney, E, Moore, D, O'Donnell, J, Price, M, Raichand, S, Riley, RD   +12 more
core   +2 more sources